Who We Are


WEST Board of Directors

Jodi Detjen, Clinical Professor of Management at Suffolk University 

Ann DeWitt, Ph.D., Senior Director of Investments and Principal at Sanofi-Genzyme BioVentures 

Alison Elworthy, VP of Operations and Chief of Staff at HubSpot

Natasha EnganSVP of Global Consulting at Deltek

Sandra Glucksmann, Ph.D., WEST Chair

Debbie Gustafson, Chief Executive Officer of Energetiq Technology, Inc.

Danielle Lauzon, J.D., Partner in Goodwin Procter LLP’s Technology Companies & Life Sciences Group

Joel MacAuslan, Ph.D., Chief Executive and Chief Science Officer of STAR Analytical Services

Mariana Nacht, Ph.D., VP Cancer Biology, KDAc Therapeutics

Mary Ann O’Loughlin, Regional Corporate Relations Director in Executive Education at Harvard Business School

Jen Zarutskie Sieczkiewicz, J.D., Ph.D., Research and Business Development Counsel at Biogen, Inc.

Jo Viney, Ph.D., Co-founder and CSO at a new startup biotech company

Shelia Violette, Ph.D., Entrepreneur in Residence Atlas Venture



Director of Operations


Jaime Luna joined WEST in 2012 and serves as Director of Operations. She comes to WEST with extensive experience in nonprofit organizations, specifically in program operations and project management. Jaime served as Director of Program Operations for Illumination Foundation working with homeless families and individuals. As a key member, she helped the grassroots nonprofit grow from its infancy to a $2,000,000 organization in three short years. She developed, supervised and created systems, policies and procedures for programs. Jaime organized operations' strategic planning by creating and executing objectives, strategies, and tactics to achieve long term goals. 

Previous to Illumination Foundation, Jaime worked at theYMCA of Metropolitan Los Angeles, Camping Services. She filled in the role of Operations Executive Director.  During this time she created effective office systems and implemented a camp contract management system. She oversaw the operation of many YMCA camps and developed, monitored, and managed related annual operating budgets of over $2,000,000, including human resources, office administration, accounts receivable, accounts payable, payroll, and procurement. 

Jaime completed her Master's (MA) degree in Education. She planned and implemented a program of instruction that provided for effective teaching strategies and maximized time on task while meeting the individual needs of students. Jaime executed a classroom management plan and supported student's physical, social, and emotional growth.

Board of Directors


Alexandra (Sandra) Glucksmann, 
Ph.D., is Chief Operating Officer at Editas Medicine Inc., a gene editing company whose mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of genetic diseases. Alexandra was most recently Senior Vice President of Research and Development at Cerulean Pharma, which she joined at its founding. Cerulean Pharma is a clinical-stage company developing innovative nanopharmaceutical tumor-targeting products. She was brought in by founders and investors to help build Tempo (renamed Cerulean) from the ground up. She was a key contributor to all aspects of building the company including setting the strategy, analyzing product development opportunities, cultivating platform and product partnership prospects and participating in fundraising activities. Prior to joining Cerulean in 2006, she spent 13 years at Millennium Pharmaceuticals which she joined in 1993 as one of its first scientists. At Millennium, she held a series of positions with increasing responsibility, ultimately becoming Vice President of all platform technology groups before moving into a senior role in strategic program management and operations. In this role, she worked closely with the CEO and led company-wide process improvement initiatives and participated in business development and M&A efforts. During her tenure at Millennium, Alexandra was critical in helping Millennium evolve from a genomics research-focused organization to a fully integrated and commercial pharmaceuticals company.  Her division played an integral role in the numerous Millennium-large pharma collaborations, which generated over $1.8 billion in funding for the company. She serves on the Board of Directors of Taconic Farms and is the Chair of the Board of Women in the Enterprise of Science and Technology (WEST). She is also a member of the Advisory Council of the Harvard Partners Center for Personalized Genetic Medicine. Alexandra was a post-doctoral fellow at the Massachusetts Institute of Technology and holds a Ph.D. with honors from the University of Chicago.



Dr. Jo Viney is Co-founder and CSO at a new startup biotech company.  Prior to that Jo was Senior Vice President, Drug Discovery at Biogen in Cambridge, MA. In this role, Jo was responsible for setting scientific research direction and strategy with a focus on target identification and validation for drug discovery and development for treating patients with autoimmune and inflammatory diseases.

Jo received her PhD from St Bartholomew’s Hospital, University of London in 1991 and pursued postdoctoral fellowships first at the Imperial cancer Research Fund in London, UK, and at Genentech in the Bay Area, California. Following her training, Jo joined Immunex in 1995 and remained at the company, which was acquired by Amgen in 2002, until leaving to join Biogen Idec.

Jo has advanced a portfolio of novel biologic and small molecule programs, seven of which have progressed to IND and into clinical development, for diseases such rheumatoid arthritis, asthma, atopic dermatitis, psoriasis, inflammatory bowel disease and lupus.

Jo has maintained longstanding membership with the American Society of Immunologists (AAI), the British Society for Immunology (BSI) and the Society for Mucosal Immunology (SMI). She served as President of SMI from 2011-2013. Together with her SMI colleagues, she launched the journal Mucosal Immunology with Nature Publishing Group in 2007.

Jo has been a member of the Scientific Advisory Board for Keystone Symposia since 2008, and she partners with KS on a number of programs for under-represented scientists. She is also member of the Scientific Advisory Board for the BioAster Technology Research Institute (IRT) in France, and for Vaxart Inc in the Bay Area. 


Board Members:


Jodi Detjen is a clinical professor of management at Suffolk University and is the MBA program director. She co-authored The Orange Line: A Woman’s Guide to Integrating Career, Family and Life in May 2013. She focuses on consulting and leadership development on these principles in her consulting firm, Orange Grove Consulting. Her vision is to help organizations globally achieve gender parity in leadership. 

Jodi has been consulting around leadership and organizational effectiveness for over 25 years. She teaches, consults and writes in areas of leadership development, managing change, increasing impact, and how women can realize their power.  

Jodi teaches management at the MBA, Undergraduate and Executive Education levels online, in the classroom and internationally. Jodi teaches the way adults learn through interaction and application of the concepts.

Formerly, Jodi was a founding partner of a boutique consulting firm, the InTrinsic Group, guiding organizations to leverage their existing people and processes to maximize performance and long term impact. Prior to teaching Jodi was an international management consultant based in London, England working with Global 1000 clients. Jodi focused on redesigning operations thereby realizing significant financial benefits. Her MA in International Development Policy is from Duke University and her B.Sc., from Virginia Tech in Management Science. 



Ann DeWitt is a Senior Director of Investments and Principal at Sanofi-Genzyme BioVentures, the corporate venture capital group of Sanofi. She joined SGBV in 2013 with a background in biotech partnering and early stage investment. Prior to SGBV, Ann was Senior Director, Corporate Development at Permeon Biologics, a Flagship Venture’s co-founded company. Previously, she was a Senior Associate at Flagship Ventures, an early stage venture capital firm investing in healthcare companies with $1.4 billion under management and was a Board observer for several portfolio companies including Taris Biomedical, Pervasis Therapeutics, and VisEn Medical. Post-doctorate, she worked at 3M Company in corporate research and in business units, including 3M Pharmaceuticals, and was a Technical Circle of Excellence Award winner.

Ann is a long-time member of the Life Sciences Council of Springboard Enterprises, an organization dedicated to building high-growth technology-oriented companies led by women.

Ann holds a B.S. from the University of Illinois in engineering, a Ph.D. from MIT in systems biology, and an M.B.A. from Harvard Business School.



Alison Elworthy is the VP of Operations and Chief of Staff at HubSpot, where she is responsible for HubSpot's operating system, pricing and packaging, strategic planning, and ultimately, keeping the company on track as the world's leading inbound marketing and sales platform. 

Prior to her role as VP and Chief of Staff, Alison led various functions at HubSpot as Marketing Operations Manager, Sales Operations Senior Manager, and Director of Operations. She was previously a User Experience Specialist at Fidelity Investments, focused on the customer experience of their business and customer facing products and websites. 

Alison serves on the board for the non-profit WEST. Outside of work, she is a wine and food enthusiast. She holds a BS in Human Factors Engineering from Tufts University and an MBA from the Tuck School of Business at Dartmouth.



Natasha Engan is the SVP of Global Consulting at Deltek. Prior to that, she was Vice President of IBM Security Financial Services Market. Her responsibilities included business ownership for the security services and security software within the Financial Services Market.

Prior to this position, Ms. Engan was the Vice President of Security Services, IBM Security North America.  In this role Ms. Engan had general management responsibility for IBM's Security Services businesses including strategy, P&L management, direct and indirect sales, delivery, and client satisfaction.

Ms. Engan has held a number of other leadership roles including the Vice President of IBM Cloud Services in North America.  In this role, Ms. Engan had responsibility for the overall executive management of IBM's cloud services businesses including strategy, market selection, day-to-day sales, P&L management, partner strategy and customer satisfaction.  She also served as the Vice President of IBM Global Services, Solutions Sales, for the Western United States. In that capacity Ms. Engan led IBM ITS's sales initiatives around IT Strategy and Design, Data Center Services, Integrations Communications, End User support, Business Continuity and Resiliency, Security, and Mobility service offerings.

Ms. Enganjoined IBM in 2005 via the Ascential Software acquisition.  She has a strong transactional software and Saas background with experience in product marketing, managing both services sales and delivery teams, implementing global delivery models worldwide, and working as a regional services leader in Asia Pacific.

Natasha holds a BA from Mount Holyoke College in Chemistry and Environmental Science and completed the Executive Program at Louisiana State University. She resides with her and two children in the Boston Area.



Debbie Gustafson is the Chief Operating Officer of Energetiq Technology, Inc., a high tech equipment company. Debbie is a hands-on executive and leader with a proven track record of organizational success in the semiconductor and related industries. She is an expert in operations and sales & marketing. She has vast international experience including Asia, Europe, and Israel and is experienced in negotiating large, complex and multifaceted contracts and supplier agreements. In a prior role she has opened up offices and joint ventures in Japan and Korea.  She has held strategic marketing and sales positions at Mykrolis (Entegris), ASTeX (MKS), Teradyne and Helix (Brooks Automation). She holds a BS in Mechanical Engineering from Southeastern Massachusetts University (UMass Dartmouth) and an MBA in Management from Bentley University. 



Danielle Lauzon is a partner in Goodwin Procter LLP’s Technology Companies & Life Sciences Group. Danielle’s representation of start-up and later stage companies spans the entire corporate life cycle, including formation matters, general corporate representation and counseling, venture capital financings, public offerings and mergers and acquisitions. Her clients are in the life sciences, software and healthcare information technology services industries. Prior to joining Goodwin Procter in 2005, Danielle was an associate in the Business Practice Group at Testa, Hurwitz & Thibeault in Boston. Danielle is a member of the Massachusetts and Boston Bar Associations. Danielle holds a J.D. from Villanova University School of Law (magna cum laude, Order of the Coif) and a B.A. from the University of Michigan.



Joel MacAuslan, Ph.D., is Chief Executive and Chief Science Officer of STAR Analytical Services, which provides mathematical and analytical capability for clients' innovation projects that require expertise in system modeling, signal processing, and nonlinear dynamics - from brain surgery to rocket science. He founded STAR on an NIH grant to apply techniques of chaos theory to the dynamics of the larynx. Joel has participated actively in WEST since early 2000. Joel holds a Ph.D. in Astrophysics from Cornell and has spent over twenty-five years in mathematical speech, signal, and image-processing analysis.



Mariana Nacht, Ph.D., is currently VP Cancer Biology, KDAc Therapeutics, Cambridge with 19 years of experience in biotechnology. Prior to Torus, she was VP and Head of Biology at Padlock Therapeutics and one of the first employees at Avila Therapeutics and directed the biology team. Avila was a start-up biotech company dedicated to discovering and developing irreversible small molecule inhibitors of kinases and proteases for oncology and infectious diseases. During those 5 years, three drug candidates were discovered, and two were advanced to clinical trials (the BTK inhibitor CC-292, and the mutant selective EGFR inhibitor CO-1686, partnered with Clovis Oncology). After the acquisition of Avila by Celgene in 2012, Mariana continued to lead biology research at Celgene Avilomics Research before joining Padlock as an early member of the executive team. Mariana started her biotech career at Genzyme, where she worked for ten years, focusing on various aspects of human oncology including the study of proteins that promote or prevent tumor angiogenesis and growth. Mariana received her B.S. in Biology from Tufts University and a Ph.D. from the University of Pennsylvania. She continued her training as a post-doctoral fellow in the laboratory of Tyler Jacks at MIT before continuing her career in industry.



Mary Ann O’Loughlin is Regional Corporate Relations Director in Executive Education at Harvard Business School (HBS) where she leads the team supporting corporate clients in Europe, the Middle East, and Africa.

Her global business career has spanned sales, marketing, consulting, and senior management roles in large corporations and small start-ups. She has lived and worked in Canada, France, the United States, and the United Kingdom.

Prior to joining HBS in 2007, Mary Ann spent ten years with the UK research and consulting company Ovum in both London and Boston. In addition to her own work as a telecoms sector Principal Consultant, she managed Ovum’s US operation as President of Ovum North America for five years. Previously, Mary Ann had founded and managed a consulting and telecoms service company in France and, earlier in her career, she worked for IBM Canada, Hewlett Packard and Alcatel in senior sales and product marketing positions.

Mary Ann holds a BS in Physics from McMaster University (Ontario), an MS in Biophysics from the University of Toronto, an MBA from Insead, and a graduate certificate in Executive Coaching from the William James College. 

A UK native, Mary Ann lives in Boston. She is a fluent French speaker.



Jen Zarutskie Sieczkiewicz is Research and Business Development Counsel at Biogen, Inc., where she serves as lead asset team counsel for several rare disease programs, advising on matters relating to clinical trials, program management, contract interpretation, regulatory approval and exclusivity, labeling, global commercial strategy and R&D and clinical compliance regulations. 

Prior to assuming this role in 2014, Jen practiced intellectual property law for well over a decade, most recently as Director of IP Strategy and Operations at Biogen, where she aligned IP strategy with the company’s R&D, corporate and commercial strategies and managed the IP operations.  Prior to moving to Biogen, she was Director of IP at Dyax Corp and also spent time in firm practice, most recently at Foley Hoag LLP, counseling on a range of IP matters. 

Jen continues to be active in the Boston Patent Law Association, having served as the Activities and Public Relations Chair in 2015 and Chair of the Biotechnology Committee for several years prior.   She also engages in other volunteer roles outside work, currently serving as Treasurer of the Fletcher-Maynard Academy Parent-Teacher Organization in Cambridge, MA.

Jen received her J.D. from Boston University Law School, her Ph.D., in Biological Chemistry from MIT, and her A.B. in Chemistry from Bryn Mawr College.   



Shelia Violette, Ph.D. is Entrepreneur in Residence Atlas Venture with more than 20 years of industry experience in translational research and drug development.  She has been responsible for driving the strategic direction of multi-disciplinary teams of scientists and academic collaborators and advancing therapeutic candidates from early discovery research to clinical development.  Prior to Biogen, Shelia was Vice President of Research at Stromedix and a member of the senior management team.  Over the last 20 years she has provided leadership and scientific direction for several research groups in the areas of inflammation, fibrosis, autoimmunity and oncology at Biogen, Ariad and Repligen.  A particular area of interest has been developing therapeutics that target members of the integrin family of proteins for diseases with high unmet clinical need. She initiated and led the avb6 antibody program and advanced its development from research to early clinical trials in patients with idiopathic pulmonary fibrosis. 

Shelia has been an organizer and speaker for several international and national scientific meetings and is a member of the Pulmonary Fibrosis Foundation Research Advisory Forum.  She has authored more than 70 scientific publications and multiple patent applications. Shelia received her Ph.D. in Pharmacology from Yale University and carried out her post-doctoral training with Frank Ruddle in the Department of Biology at Yale University.

Chair Emeritus:

Janice Bourque is former Senior Vice President and Group Head-Life Sciences for Comerica Bank where she was responsible for leading Comerica’s national strategy for the life sciences. Prior to that, Ms. Bourque was President/CEO of the Massachusetts Biotechnology Council (MBC) where she led the organization for 12 years. In 2004, she was awarded the Woman of Valor Award by the American Diabetes Association and the 2004 Distinguished Leadership Award by the Huntington Disease Society for her work in public policy and public health. In 2003, Boston Magazine named her one of Boston’s 100 most influential women and the Cambridge Chamber Commerce awarded her Business Person of the Year. Ms. Bourque received her MBA degree in finance and accounting and her BS degree in veterinary science from the University of New Hampshire.